GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (FRA:8640) » Definitions » Other Current Assets

Lixte Biotechnology Holdings (FRA:8640) Other Current Assets : €0.10 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Lixte Biotechnology Holdings Other Current Assets?

Lixte Biotechnology Holdings's other current assets for the quarter that ended in Dec. 2023 was €0.10 Mil.

Lixte Biotechnology Holdings's quarterly other current assets declined from Jun. 2023 (€0.17 Mil) to Sep. 2023 (€0.12 Mil) and declined from Sep. 2023 (€0.12 Mil) to Dec. 2023 (€0.10Mil).

Lixte Biotechnology Holdings's annual other current assets declined from Dec. 2021 (€0.24 Mil) to Dec. 2022 (€0.20 Mil) declined from Dec. 2022 (€0.20 Mil) to Dec. 2023 (€0.10 Mil).


Lixte Biotechnology Holdings Other Current Assets Historical Data

The historical data trend for Lixte Biotechnology Holdings's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings Other Current Assets Chart

Lixte Biotechnology Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.13 0.24 0.20 0.10

Lixte Biotechnology Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.23 0.17 0.12 0.10

Lixte Biotechnology Holdings Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Lixte Biotechnology Holdings Other Current Assets Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Lixte Biotechnology Holdings (FRA:8640) Business Description

Traded in Other Exchanges
Address
680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101
Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.

Lixte Biotechnology Holdings (FRA:8640) Headlines

No Headlines